Glutamatergic System Counteracts NMDA Dysfunction in Schizophrenia Models BPC-157s glutamate modulation carries particular promise for treatment-resistant schizophrenia and NMDA receptor hypofunction disorders
Behavioral modification strategies may include: altering the concentration and/or volume of urine, either by fluid restriction or additional hydration
Since the 1993 discovery of the first miRNA, lin-4, in the nematode C
Leaner individuals should use 45 degrees
developed biodegradable nanocomposite microspheres encapsulating DFP to enhance mucoadhesion and sustain drug release for nasal administration (Boyuklieva et al., 2024), although in vitro and in vivo efficacy data are still lacking
15, 30 June 2025, 100188, Pich, Marie-Eve, Andr Tchernof, and Jean-Pierre Desprs